Normocalcemic Primary Hyperparathyroidism in Adults Without a History of Nephrolithiasis or Fractures: A Prospective Study

Abstract

The prevalence and the diagnostic criterion of “normocalcemic” primary hyperparathyroidism (NPHPT) are still uncertain and there is no consensual definition. This prospective study evaluated the prevalence of NPHPT in 676 adults without a history of fractures or nephrolithiasis and who would be submitted to thyroidectomy, the impact of adopting different cut-off values for 25-hydroxyvitamin D and estimated glomerular filtration rate (eGFR), and the agreement between biochemical diagnosis and the surgical finding of altered parathyroid glands. NPHPT was diagnosed in patients with normal total and ionized calcium and elevated PTH (in 2 measurements) and without a known cause of secondary HPT, including eGFR<40 ml/min/1.73 m² and 25-hydroxyvitamin D<20 ng/dl. The 4 parathyroid glands were fully explored in these patients. Forty-six patients (6.8%) had a laboratory diagnosis of NPHPT. Altered parathyroid glands were detected in only 4 patients, corresponding to 0.6% of all patients and to 8.7% of those with a biochemical diagnosis of NPHPT. The latter was confirmed in 0/174 men, 1/252 premenopausal women, and 3/250 postmenopausal women. Among the 42 patients with elevated PTH and without altered parathyroid glands, 25 had 25-hydroxyvitamin D between 20 and 30 ng/dl, 7 had eGFR between 40 and 60 ml/min/1.73 m², and 9 had both. The prevalence of NPHPT was 0.74% in this adult population without a history of nephrolithiasis or fractures. The diagnostic criterion using eGFR>60 ml/min/1.73 m² and 25-hydroxyvitamin D>30 ng/dl was more appropriate considering the agreement with the surgical finding of altered parathyroid glands.

Key words

primary hyperparathyroidism - normocalcemic - secondary hyperparathyroidism - diagnosis - prevalence

• References

• 1 Zini M, Attanasio R, Cesareo R. et al. AME position statement: Primary hyperparathyroidism in clinical practice. J Endocrinol Invest 2012; 35 (7 Suppl): 2-21
• 2 Eastell R, Brandi ML, Costa AG. et al. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3570-3579
• 3 Wilhelm SM, Wang TS, Ruan DT. et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016; 151: 959-968
• 4 Khan AA, Hanley DA, Rizzoli R. et al. Primary hyperparathyroidism: Review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 2017; 28: 1-19
• 5 Babwah F, Buch HN. Normocalcaemic primary hyperparathyroidism: A pragmatic approach. J Clin Pathol 2018; 71: 291-297
• 6 Bilezikian JP, Brandi ML, Eastell R. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3561-3569
• 7 Udelsman R, Åkerström G, Biagini C. et al. The surgical management of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3595-3606
• 8 García-Martín A, Reyes-García R, Muñoz-Torres M. Normocalcemic primary hyperparathyroidism: One-year follow-up in one hundred postmenopausal women. Endocrine 2012; 42: 764-766
• 9 Cusano NE, Maalouf NM, Wang PY. et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013; 98: 2734-2741
• 10 Kontogeorgos G, Trimpou P, Laine CM. et al. Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol (Oxf) 2015; 83: 277-284
• 11 Lowe H, McMahon DJ, Rubin MR. et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92: 3001-3005
• 12 Marques TF, Vasconcelos R, Diniz E. et al. Normocalcemic primary hyperparathyroidism in clinical practice: An indolent condition or a silent threat?. Arq Bras Endocrinol Metabol 2011; 55: 314-317
• 13 Bandeira F, Griz L, Chaves N. et al. Diagnosis and management of primary hyperparathyroidism - a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metabol 2013; 57: 406-424
• 14 Vignali E, Cetani F, Chiavistelli S. et al. Normocalcemic primary hyperparathyroidism: A survey in a small village of Southern Italy. Endocr Connect 2015; 4: 172-178
• 15 Lundgren E, Rastad J, Thrufjell E. et al. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997; 121: 287-294
• 16 Rosário PW, Mourão GF, Calsolari MR. Screening for hyperparathyroidism by measurement of calcium in patients undergoing thyroid surgery: A prospective study. Horm Metab Res 2016; 48: 673-676
• 17 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 18 Denizot A, Dadoun F, Meyer-Dutour A. et al. Screening for primary hyperparathyroidism before thyroid surgery: A prospective study. Surgery 2002; 131: 264-269
• 19 Šiprová H, Fryšák Z, Souček M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat?. Endocr Pract 2016; 22: 294-301